Ascendis Pharma · 3 months ago
Director, Finance Gross-to-Net Reporting - Job ID: 1810
Princeton, NJ
Full-time
Onsite
Director/Executive
$190K/yr - $220K/yr
10+ years expAscendis Pharma is a dynamic, fast-growing global biopharmaceutical company focused on advancing programs in Endocrinology Rare Disease and Oncology. The Director, Finance Gross-to-Net Reporting will lead the development and oversight of government pricing and GTN analytics across the U.S. business, ensuring compliance with pricing regulations while maximizing net revenue.
BiotechnologyClinical TrialsHealth Care
Responsibilities
Lead the GTN efforts, including modeling, forecasting, accruals, and scenario planning to inform financial planning and product pricing decisions
Partner cross-functionally with Market Access, Trade, Patient Support Services, Analytics & Commercial Operations, other US Commercial teams, Global Finance, and Legal teams to inform GTN forecast, assess and optimize pricing strategies, and net revenue performance
Guide the design and enhancement of automation tools and dashboards to streamline data aggregation, analytics, and executive reporting for GTN and government pricing
Serve as a key contributor in the implementation of new legislation (e.g., Inflation Reduction Act), including development of pricing strategies, modeling, and policy impact assessments
Lead the end-to-end government pricing reporting and operations, including oversight of calculations, compliance, and reporting for programs such as AMP, BP, PHS, FSS/VA, ASP, nFAMP, FCP, IFF, and URA
Oversee the development and maintenance of SOPs, assumptions documentation, and procedural controls to ensure audit readiness and policy alignment
Manage reviews and approvals of monthly accruals, reconciliations, utilization files (e.g., rebates, 340B claims, disputes), and reporting packages to ensure accuracy and compliance
Stay abreast of industry trends, policy changes, and regulatory updates; evaluate their potential impact on GTN, pricing strategy, and financial forecasts
Serve as the primary point of contact for internal and external audits related to government pricing or GTN
Champion cross-functional initiatives related to FMV analysis, bona fide service fees, state transparency reporting, and other pricing-related special projects
Qualification
Required
Bachelor's degree required; advanced degree (MBA, MHA, Finance, or related field) strongly preferred
Minimum 10+ years of progressive experience in pharmaceutical finance, pricing, market access, or government programs, with at least 5 years in a leadership or strategic role
Strong command of GTN forecasting, accrual methodology, and related analytics and reporting
Deep expertise in U.S. Federal and State Pricing Programs (Medicaid, Medicare, FSS, PHS340B) and related regulations
Deep experience working in therapeutic areas with managed care contracting and rebates
Demonstrated ability to lead cross-functional initiatives and influence senior stakeholders
Experience developing and managing financial models and pricing strategies in a commercial biotech or pharma environment
Proven ability to manage compliance risk in a dynamic and regulated environment
Exceptional analytical, problem-solving, and communication skills
High attention to detail, with a strategic mindset and ability to see the big picture
Benefits
401(k) plan with company match
Medical, dental, and vision plans
Company-offered Life and Accidental Death & Dismemberment (AD&D) insurance
Company-provided short and long-term disability benefits
Unique offerings of Pet Insurance and Legal Insurance
Employee Assistance Program
Employee Discounts
Professional Development
Health Saving Account (HSA)
Flexible Spending Accounts
Various incentive compensation plans
Accident, Critical Illness, and Hospital Indemnity Insurance
Mental Health resources
Paid leave benefits for new parents
Company
Ascendis Pharma
Ascendis Pharma built a high-value pipeline that aims to change the clinical treatment paradigms.
1001-5000 employees
Funding
Current Stage
Public CompanyTotal Funding
$1.88BKey Investors
Royalty Pharma
2024-09-19Post Ipo Equity· $300M
2024-09-03Post Ipo Debt· $150M
2023-09-05Post Ipo Debt· $150M
Leadership Team
Ivanna Rosendal
Senior Director, IT Business Partner
Keren Tenenbaum
US General Counsel and Chief Compliance Officer
Recent News
2026-01-11
2026-01-11
Company data provided by crunchbase